Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
High-mobility group box 1 (HMGB1) functions as a proinflammatory cytokine and is one of the most intriguing molecules in inflammatory disorders and cancers. Notably, HMGB1 is a potential therapeutic target and novel biomarker in related diseases. However, the diagnostic value of HMGB1 for benign and malignant asbestos-related diseases (ARDs) remains unclear. In this work, we detected preoperative serum HMGB1 levels in Chinese asbestos-exposed (AE) and ARDs populations and further evaluated the diagnostic value of HMGB1 in patients with certain types of ARDs, including those with pleural plaques, asbestosis, or malignant mesothelioma (MM). The experimental data presented that the serum level of HMGB1 was significantly elevated in AE and ARDs subjects. Our findings indicated that serum HMGB1 is a sensitive and specific biomarker for discriminating asbestosis- and MM-affected individuals from healthy or AE individuals. In addition, serum matrix metalloproteinases 2 and 9 are not correlated with HMGB1 in ARDs. Thus, our study provides supporting evidence for HMGB1 as a potential biomarker either for the clinical diagnosis of high-risk AE cohorts or for evaluating ARDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“High levels in the blood of both subjects exposed to asbestos and mesothelioma patients have been demonstrated [62].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HMGB1 and RAGE in Inflammation and Cancer
Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R., & Coyle, A. J. (2010) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132603 · Cited by 1,436 · cited 2×
“Increasing clinical evidence indicates that extracellular HMGB1 contributes to inflammatory disorders and cancer development [5, 6, 32].”
BackgroundMatrix metalloproteinases (MMPs): Chemical–biological functions and (Q)SARs
Verma, R. P., & Hansch, C. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.01.011 · Cited by 783 · cited 1×
“It is well known that MMPs are involved in the process of metastasis formation and that their overexpression correlates with the processes of tumor cell invasion and metastasis in human cancers by degrading the extracellular matrix [45, 46].”
BackgroundHigh-mobility group box 1 and cancer
Tang, D., Kang, R., Zeh III, H. J., & Lotze, M. T. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.11.014 · Cited by 512
Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas
Cathcart, J., Pulkoski-Gross, A., & Cao, J. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2014.12.002 · Cited by 504 · cited 1×
“It is well known that MMPs are involved in the process of metastasis formation and that their overexpression correlates with the processes of tumor cell invasion and metastasis in human cancers by degrading the extracellular matrix [45, 46].”
BackgroundHMGB1 in Cancer: Good, Bad, or Both?
Kang, R., Zhang, Q., Zeh, H. J., Lotze, M. T., & Tang, D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0495 · Cited by 493
Husain, A. N., Colby, T., Ordonez, N., Krausz, T., Attanoos, R., Beasley, M. B., Borczuk, A. C., Butnor, K., Cagle, P. T., Chirieac, L. R., et al. (2013) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2012-0214-oa · Cited by 473 · cited 1×
“MPM was diagnosed by at least two independent pathologists according to the Guidelines for Pathologic Diagnosis of Malignant Mesothelioma proposed by the International Mesothelioma Interest Group [25].”
MethodAn overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies
Musumeci, D., Roviello, G. N., & Montesarchio, D. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.001 · Cited by 334 · cited 1×
“Novel strategies targeting HMGB1, such as glycyrrhizin [37], gabexate mesilate [37], ethyl pyruvate [38, 39], and PPAR ligands [40] that interfere with asbestos-mediated inflammation, may prevent or delay ARDs onset and relieve the progress of malignant ARDs.”
BackgroundYang, H., Rivera, Z., Jube, S., Nasu, M., Bertino, P., Goparaju, C., Franzoso, G., Lotze, M. T., Krausz, T., Pass, H. I., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006542107 · Cited by 281
Cancer Cell Secretion of the DAMP Protein HMGB1 Supports Progression in Malignant Mesothelioma
Jube, S., Rivera, Z. S., Bianchi, M. E., Powers, A., Wang, E., Pagano, I., Pass, H. I., Gaudino, G., Carbone, M., & Yang, H. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3481 · Cited by 255 · cited 2×
“One group from the USA provided the first evidence that HMGB1 was highly expressed in both tissues and sera of mesothelioma patients [20].”
BackgroundDiagnosis and Initial Management of Nonmalignant Diseases Related to Asbestos
Smith, D. D. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.171.6.951 · Cited by 252
Cited by
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., Bölükbas, S., Boyd, J., Coolen, J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00953-2019 · Cited by 273
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Opitz, I., Scherpereel, A., Berghmans, T., Psallidas, I., Glatzer, M., Comas, D. R., Astoul, P. J., Bölükbas, S., Boyd, J., Coolen, J., et al. (2020) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezaa158 · Cited by 120
Epidemiology of Environmental Exposure and Malignant Mesothelioma
Liu, B., van Gerwen, M. A. G., Bonassi, S., & Taioli, E. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.002 · Cited by 117
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update
Chen, Z., Gaudino, G., Pass, H. I., Carbone, M., & Yang, H. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.05.06 · Cited by 95
“Consistently, we found that HMGB1 levels in serum and plasma were higher in MM patients compared to healthy individuals (Figure 1) (78) and these findings were confirmed by other studies reporting significantly higher serum HMGB1 levels in MM patients compared to individuals with benign asbestos-related diseases (79,8…”
ResultBiomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on
Ledda, C., Senia, P., & Rapisarda, V. (2018) · Cancers · doi:10.3390/cancers10060203 · Cited by 62
“Scientific studies have shown that HMGB1 serum levels are higher in MM patients than in asbestos-only controls (not affected by MM) [78].”
BackgroundSchillebeeckx, E., van Meerbeeck, J. P., & Lamote, K. (2021) · European Respiratory Review · doi:10.1183/16000617.0057-2021 · Cited by 61
Johnen, G., Burek, K., Raiko, I., Wichert, K., Pesch, B., Weber, D. G., Lehnert, M., Casjens, S., Hagemeyer, O., Taeger, D., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-32315-3 · Cited by 53
Zolondick, A. A., Gaudino, G., Xue, J., Pass, H. I., Carbone, M., & Yang, H. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-21-12 · Cited by 41
“Accordingly, asbestos-exposed individuals have elevated HMGB1 serum levels and its levels further increased during mesothelioma development, suggesting that HMGB1 can be a potential biomarker for asbestos exposure and early detection of mesothelioma (4,39,57,58).”
BackgroundFiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39
“High levels in the blood of both subjects exposed to asbestos and mesothelioma patients have been demonstrated [62].”
BackgroundPass, H. I., Alimi, M., Carbone, M., Yang, H., & Goparaju, C. M. V. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0083 · Cited by 39
“Serum HMGB1 level was found to be higher in patients with MPM compared to nonMPM asbestos-exposed individuals (161).”
ResultSaleh, D. M., Luo, S., Ahmed, O. H. M., Alexander, D. B., Alexander, W. T., Gunasekaran, S., El‐Gazzar, A. M., Abdelgied, M., Numano, T., Takase, H., et al. (2022) · Particle and Fibre Toxicology · doi:10.1186/s12989-022-00469-8 · Cited by 40
HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma
Wang, Y., Jiang, Z., Yan, J., & Ying, S. (2019) · Disease Markers · doi:10.1155/2019/4183157 · Cited by 39
“However, no significant differences in HMGB1 levels were observed between the two groups with different exposure durations (AE < 10 and AE ≥ 10 years) AE [59].”
BackgroundResultInfluentialSelf-citationFour-miRNA Signature to Identify Asbestos-Related Lung Malignancies
Santarelli, L., Gaetani, S., Monaco, F., Bracci, M., Valentino, M., Amati, M., Rubini, C., Sabbatini, A., Pasquini, E., Zanotta, N., et al. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-0453 · Cited by 35
“Various candidates for biomarkers of asbestos-related malignancies have been proposed (6-8).”
BackgroundFiletti, V., Falzone, L., Rapisarda, V., Caltabiano, R., Graziano, A. C. E., Ledda, C., & Loreto, C. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.110640 · Cited by 33
Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
Sorino, C., Mondoni, M., Marchetti, G., Agati, S., Inchingolo, R., Mei, F., Flamini, S., Lococo, F., & Feller-Kopman, D. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12227006 · Cited by 32
“Few studies that show a high accuracy of the marker in terms of distinguishing asbestosis patients from healthy patients with and without asbestos exposure are present in the literature (AUC ROC : 0.88) [115].”
BackgroundInfluentialJiang, Z., Ying, S., Shen, W., He, X., Chen, J., Xia, H., Yu, M., Xiao, Y., Feng, L., Zhu, L., et al. (2017) · Disease Markers · doi:10.1155/2017/1725354 · Cited by 22
“example, HMGB1 was thought to be a potential indicator for screening severe ARDs and evaluating high-risk AE cohorts in our previous work [18].”
BackgroundMethodSelf-citationFiletti, V., Vitale, E., Broggi, G., Hagnäs, M. P., Candido, S., Spina, A., & Lombardo, C. (2020) · Biomedical Reports · doi:10.3892/br.2020.1367 · Cited by 26
Aberrant Expression of High Mobility Group Box Protein 1 in the Idiopathic Inflammatory Myopathies
Day, J. A., Otto, S., Cash, K., Eldi, P., Hissaria, P., Proudman, S., Limaye, V. S., & Hayball, J. D. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00226 · Cited by 17
MicroRNA-Mediated Regulation of HMGB1 in Human Hepatocellular Carcinoma
Yan, J., Ying, S., & Cai, X. (2018) · BioMed Research International · doi:10.1155/2018/2754941 · Cited by 16
Self-citationSignificance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women
Ramezani, A., Aghakhani, A., Soleymani, S., Bavand, A., & Bolhassani, A. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-3780-2 · Cited by 16
“in a variety of inflammatory disorders and cancers [27, 28].”
BackgroundThe Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma
Lettieri, S., Bortolotto, C., Agustoni, F., Lococo, F., Lancia, A., Comoli, P., Corsico, A. G., & Stella, G. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051034 · Cited by 17
“Within respect to the epidemiologic perspective, serologic levels of HMGB1 have been validated as predictive biomarker for monitoring occupational workers and their families who have a history of exposure to asbestos [72].”
BackgroundATG5 as biomarker for early detection of malignant mesothelioma
Tomasetti, M., Monaco, F., Strogovets, O., Volpini, L., Valentino, M., Amati, M., Neužil, J., & Santarelli, L. (2023) · BMC Research Notes · doi:10.1186/s13104-023-06330-1 · Cited by 13
“High levels of circulating HMGB1 and ATG5 were found in asbestos-exposed subjects as a result of autophagic activation [10].”
BackgroundPass, H. I., Alimi, M., Carbone, M., Yang, H., & Goparaju, C. M. V. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.08.001 · Cited by 11
Fibulin-3 Immunoexpression in Malignant Mesothelioma Due to Fluoro-Edenite: A Preliminary Report
Caltabiano, R., Loreto, C., Vitale, E., Matera, S., Miozzi, E., Migliore, M., Angelico, G., Tumino, R., Ledda, C., & Rapisarda, V. (2018) · Future Oncology · doi:10.2217/fon-2017-0386 · Cited by 10
Štrbac, D., Goričar, K., Dolžan, V., & Kovač, V. (2019) · Disease Markers · doi:10.1155/2019/1242964 · Cited by 9
“Proinflammatory cytokine HMGB1 is increased in serum of MM patients, since it drives and sustains MM development and it was proposed as an early detection biomarker and a possible drug target in MM [29, 30].”
BackgroundJiang, Z., Shen, W., Ying, S., Gao, Z., He, X., Chen, R., Xia, H., Guo, X., Fang, Y., Zhang, Y., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77412-4 · Cited by 8
Self-citationNLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseases
Franko, A., Goričar, K., Kovač, V., Dodič-Fikfak, M., & Dolžan, V. (2019) · Journal of Medical Biochemistry · doi:10.2478/jomb-2019-0025 · Cited by 8
Ananthamohan, K., Jha, R. M., & Sharma, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814259-2.00005-4 · Cited by 7
Serum diagnostic markers for malignant pleural mesothelioma: a narrative review
Wang, J., & Li, Y. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-2873 · Cited by 7
“A large-sample study (n=497) found that serum HMGB1 increased sequentially in healthy individuals, in patients with asbestos exposure for less than ten years, in patients with asbestos exposure for >10 years, in patients with pleural plaques, in patients with asbestosis, and in MPM patients (42).”
BackgroundHamad, W., Grigore, B., Walford, H., Peters, J., Alexandris, P., Bonfield, S., Standen, L., Boscott, R. A., Behiyat, D., Kuhn, I. L., et al. (2024) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-24-0713 · Cited by 4
HΜGB1/sRAGE levels differ significantly between transudates and exudates
Kotsiou, O. S., JAGIRDAR, R. M., Papazoglou, E. D., Hatzoglou, C., Gourgoulianis, K. I., & Zarogiannis, S. G. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155469 · Cited by 5
Zhang, F., Yuan, X., Sun, H.-J., Yin, X., Gao, Y., Zhang, M., Jia, Z., Yu, M., Ying, S., Xia, H., et al. (2021) · Journal of Applied Toxicology · doi:10.1002/jat.4174 · Cited by 4
“Data collection was carried out following previously described procedures (Ying et al., 2017).”
MethodSelf-citationJiang, Z., Chen, J., Chen, J., Feng, L., Jin, M., Zhong, H., Ju, L., Zhu, L., Xiao, Y., Jia, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.928839 · Cited by 4
“This finding agreed with previous work from Eastern China (20) but differed from studies in Western countries (21).”
ResultSelf-citationHorie, M., Sugino, S., Fujita, K., Endoh, S., Maru, J., Matsuzawa, T., & Ogura, I. (2025) · NanoImpact · doi:10.1016/j.impact.2025.100561 · Cited by 4
Zhu, L., Ying, S., Su, X., Yu, W., Yan, K., Shen, W., Hu, S., Jiang, Z., Xia, H., Feng, L., et al. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118357 · Cited by 4
“Data collection was carried out following previously described procedures (Ying et al., 2017).”
Self-citationFerrari, L., Iodice, S., Cantone, L., Dallari, B., Dioni, L., Bordini, L., Palleschi, A., Mensi, C., & Pesatori, A. C. (2022) · La Medicina del Lavoro · doi:10.23749/mdl.v113i6.13522 · Cited by 6
Richard, S. A. (2018) · AIMS molecular science · doi:10.3934/molsci.2018.4.183 · Cited by 4
Circulating Biomarkers and Targeted Therapy in Pleural Mesothelioma
Grant, C. R., Bazhenova, L. A., & Yun, K. M. (2025) · Cancers · doi:10.3390/cancers17233863 · Cited by 3
“Serum HMGB1 levels have demonstrated promise as a diagnostic biomarker in PM with a sensitivity of 100% and specificity of 80.28% at a cutoff of 52.16 ng/mL through a prospective trial of individuals with a long history of asbestos industry exposure in southeast China [37].”
InfluentialZwijsen, K., Heirwegh, E., Schillebeeckx, E., Marcq, E., Covaci, A., de Beeck, K. O., van Meerbeeck, J. P., Raskin, J., Janssens, A., Snoeckx, A., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2025.108893 · Cited by 3
Potential Roles of Matrix Metalloproteinases in Malignant Mesothelioma
Ying, S., Wang, Y., & Lyu, L. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.88783 · Cited by 3
“Interestingly, in our previous study, we found that serum MMP-2 and MMP-9 levels were correlated with each other in both healthy control and MM groups in a Han cohort from Eastern China [40].”
BackgroundSelf-citationBartkowiak, K., Casjens, S., Andreas, A., Ačkar, L., Joosse, S. A., Raiko, I., Brüning, T., Geffken, M., Peine, S., Johnen, G., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa232 · Cited by 4
Boğar, F., Ak, G., Metintaş, S., Ayhancı, A., & Metintaş, M. (2023) · Cancer Biomarkers · doi:10.3233/cbm-220436 · Cited by 3
“It was found that HMGB1 serum levels were higher in patients with MPM than in the healthy individual exposed to asbestos and that HMGB1 is a sensitive and specific biomarker to distinguish individuals with malignant mesothelioma [32–34].”
Zhong, Y.-F., Ding, C., Yao, C., Wang, J., Feng, M., Gong, X.-X., Yu, L., Xu, H., & Xia, H. (2025) · Toxics · doi:10.3390/toxics13060448 · Cited by 3
“Our previous findings further confirmed that serum HMGB1 levels were significantly higher in MM patients than in AE individuals, those with pleural plaques, and healthy controls [24,25].”
Screening Issues in Exposed Subjects and Early Diagnosis
Mencoboni, M., Taveggia, P., Simonassi, C., & Filiberti, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-16884-1_3 · Cited by 1
Tissue and Circulating Biomarkers in Mesothelioma
Zucali, P. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-16884-1_8
Techarang, T., Jariyapong, P., Viriyavejakul, P., Glaharn, S., Srisook, C., & Punsawad, C. (2021) · Iranian Journal of Parasitology · doi:10.18502/ijpa.v16i3.7089
“High mobility group box-1 (HMGB-1) is crucially implicated in lung diseases and acts as an independent biomarker and therapeutic target for related lung diseases (6, 7).”
BackgroundMalignant Mesothelioma: Molecular Markers
Kettunen, E., Knuutila, S., & Sarhadi, V. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-30766-0_18
Saleh, D. M., Luo, S., Ahmed, O. H. M., Alexander, D. B., Alexander, W. T., Gunasekaran, S., El-Gazzar, A. M., Abdelgied, M., Numano, T., Takase, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19634909
Additional file 1 of ATG5 as biomarker for early detection of malignant mesothelioma
Tomasetti, M., Monaco, F., Strogovets, O., Volpini, L., Valentino, M., Amati, M., Neužil, J., & Santarelli, L. (2024) · Figshare · doi:10.6084/m9.figshare.26584644
Additional file 2 of ATG5 as biomarker for early detection of malignant mesothelioma
Tomasetti, M., Monaco, F., Strogovets, O., Volpini, L., Valentino, M., Amati, M., Neužil, J., & Santarelli, L. (2024) · Figshare · doi:10.6084/m9.figshare.26584647
G�rard, M. (2023) · theses.fr (ABES) · doi:10.70675/13fa8eebz4aa6z47fdz88b1zaee99674ff4b · Cited by 1
Mesothelioma Potential: Comparative Insights and Safety Findings
Horie, M. (2026) · Springer eBooks · doi:10.1007/978-981-92-2148-6_3
Molinario, A., Caprioglio, F., Rilievo, A. A., Bianchi, M. E., & Mezzapelle, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177859
“Elevated circulating and pleural HMGB1 levels have been associated with asbestos exposure, mesothelioma development, disease stage, and clinical outcome, highlighting its potential utility for risk stratification and prognosis [180,181].”
Metadata
- Authors
- Ying, S., Jiang, Z., He, X., Yu, M., Chen, R., Chen, J., Ru, G., Chen, Y., Chen, W., Zhu, L., Li, T., Zhang, Y., Guo, X., Yin, X., Zhang, X., & Lou, J.
- Affiliations
- Zhejiang Academy of Medical Sciences (CN)
- Zhejiang Provincial People's Hospital (CN)
- Jiading District Center for Disease Control and Prevention, Shanghai 201800, China
- Corresponding author
- Lou, Jianlin
- ORCID
- Venue
- Disease Markers
- Publisher
- Wiley
- Published
- 2017
- Volume
- 2017
- Pages
- 1-9
- ISSN
- 0278-0240 (ISSN-L)
- 1875-8630
- PMC
- PMC5350493
- OpenAlex
- W2593453675
- Cited by
- 54
- References
- 48
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 7 · 2020: 11 · 2019: 7 · 2018: 6 · 2017: 3
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Disease Markers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Natural Science Foundation of Zhejiang Province (LY16H240001, QJD1602027, 81502794, 2015KYA058, 2016KYB068, 2017PY015, 11-ZC02, 2014C03030)
- Qianjiang Talents Project of Zhejiang Province (LY16H240001, QJD1602027, 81502794, 2015KYA058, 2016KYB068, 2017PY015, 11-ZC02, 2014C03030)
- National Natural Science Foundation of China (LY16H240001, QJD1602027, 81502794, 2015KYA058, 2016KYB068, 2017PY015, 11-ZC02, 2014C03030)
- Health and Family Planning Commission of Zhejiang Province (LY16H240001, QJD1602027, 81502794, 2015KYA058, 2016KYB068, 2017PY015, 11-ZC02, 2014C03030)
- Zhejiang Committee of Science and Technology (LY16H240001, QJD1602027, 81502794, 2015KYA058, 2016KYB068, 2017PY015, 11-ZC02, 2014C03030)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Keywords
- HMGB1, asbestos-related diseases, serum biomarkers, asbestos exposure, asbestosis, malignant mesothelioma, pleural plaques, MMP-2, MMP-9, diagnostic value, inflammation
- MeSH terms
- Mesothelioma, Malignant, Aged, Asbestosis, Female, Humans, Lung Neoplasms, Male, Mesothelioma, Middle Aged, Biomarkers, Tumor, Case-Control Studies, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, HMGB1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.